BMS Patient Death in Autoimmune CAR-T Therapy Zolifetocel and Gilead's $1.275 Billion Asset Acquisition
BMS Autoimmune CAR-T Zolifetocel Patient Death and Safety Concerns
A Multiple Sclerosis (MS) patient died 44 days after administration in the Phase 1 clinical trial (Breakfree-2) of Bristol Myers Squibb's (BMY) autologous CD19-targeted CAR-T therapy 'zola-cel (BMS-986353)'. A non-ICANS motor disorder occurring on day 17 of treatment did not respond to intravenous immunoglobulin (IVIG) therapy; high-dose cyclophosphamide was administered, but the condition worsened into septic pneumonia. This case underscores the risks of lymphodepletion prior to treatment and neurotoxicity in non-oncological autoimmune diseases, where tolerability standards are stricter than in oncology. Following Novartis, this safety setback is likely to prompt regulators to apply a more conservative standard when evaluating the expansion of indications for cell therapies based on rapid manufacturing platforms.
Gilead's $1.275 Billion Acquisition and the Battle for Oral IL-23R Dominance
Gilead Sciences (GILD) has acquired exclusive worldwide rights to the Phase 1 oral IL-23R inhibitor 'HCXT-2001' from China's PepStar Therapeutics with an upfront payment of $1.275 billion. This strategy aims to reshape the landscape of the $20 billion autoimmune market, currently dominated by injectables such as AbbVie's Skyrizi and Johnson & Johnson's (JNJ) Tremfya, into an oral-based market. In particular, it emphasizes differentiation through a once-daily dosing regimen due to a longer half-life compared to Johnson & Johnson's recently approved oral macrocyclic peptide, Icotyde. Gilead aims to expand market share through a combination strategy with its own IBD new drug, emvistegrast.
US Treasury's China Investment Regulations and the Cross-border Licensing Landscape
The US Treasury has officially included the biotechnology sector in the review scope of its draft investment regulations targeting China (COINS Act). While equity investments in Chinese biotech by US-based venture capital (VC) and private equity funds will be strictly limited, the global licensing out of Chinese pipelines is interpreted as being outside the direct regulatory net. Consequently, global big pharma companies are focusing more on asset acquisitions and license-in models based on upfront payments rather than equity acquisition. Amid security regulations aimed at preventing technology leakage, pharmaceutical companies are increasingly employing workaround strategies to secure highly capital-efficient early-stage Chinese assets.
Roche and Zymeworks' $813 Million Next-Generation Lung Cancer Partnership
Roche (RHHBY) has licensed in the DLL3-targeted T-cell engager 'ZW209' from Canada's Zymeworks (ZYME) for a total of $813 million. The deal includes a $55 million upfront payment, a $40 million milestone for initiating Phase 1b, and future milestones totaling $718 million plus double-digit royalties, with Roche taking charge of development after Phase 1a. This move by Roche aims to bolster its pipeline in the Small Cell Lung Cancer (SCLC) market at an early stage, following the validation of Amgen's Imdelltra. For biotechs, this is an exemplary deal structure that utilizes the financial power of large pharmaceutical companies to diversify clinical risks and secure liquidity during the early clinical stages.
The death of a Phase 1 patient treated with BMS’s Zolgensma in the autoimmune CAR-T sector, alongside the discontinuation of Novartis’s pipeline, has significantly raised the standards for neurotoxicity and chemo-preconditioning tolerability in cell therapies, acting as a short-term negative factor that delays the commercialization of CAR-T in the $20 billion autoimmune market. Conversely, Gilead's $1.275 billion upfront bet on the Phase 1 oral IL-23R inhibitor HCXT-2001 suggests an imminent paradigm shift toward oral macrocyclic peptides in the psoriasis and IBD markets currently dominated by antibody blockbusters like AbbVie's Skyrizi and J&J's Tremfya. Simultaneously, the US Treasury's COINS Act regulation is reshaping global technology transaction structures by discouraging direct equity investment in China while promoting license-ins of early-stage assets by big pharma. As seen in Roche's $813 million deal for ZW209, preemptive deal-making to secure next-generation T-cell engagers will accelerate in the SCLC targeted therapy market already captured by Amgen's Imdelltra.
Source: BioPharma Dive (rss)